SCHEMBL2628262

SCHEMBL2628262

Cc1ccc2nc(-c3ccc(N[11CH3])cc3)sc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 17/20 1.00
MAPT P10636 5/20 1.00
SNCA P37840 1/20 1.00
SULT1A1 P50225 1/20 0.72
KDM4E B2RXH2 3/20 0.70
NPC1 O15118 2/20 0.70
RAB9A P51151 2/20 0.70
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
ALDH1A1 P00352 2/20 0.70
LMNA P02545 1/20 0.70
CASP3 P42574 1/20 0.70
SMN1; SMN2 Q16637 1/20 0.70
SENP8 Q96LD8 1/20 0.70
SENP7 Q9BQF6 1/20 0.70
SENP6 Q9GZR1 1/20 0.70
GLA P06280 3/20 0.68
GAA P10253 3/20 0.68
HPGD P15428 1/20 0.64
RORC P51449 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL178156 1.00 APP (1.00) APPMAPTSNCASULT1A1KDM4E
SCHEMBL13853341 0.97 APP (0.94) APPMAPTSNCASULT1A1KDM4E
SCHEMBL12421915 0.92 APP (0.85) APPMAPTSNCASULT1A1KDM4E
SCHEMBL21771263 0.88 APP (0.78) APPMAPTSNCASULT1A1KDM4E
SCHEMBL12422217 0.87 MAPT (0.81) APPMAPTSNCAKDM4ENPC1
SCHEMBL5777616 0.87 MAPT (0.76) APPMAPTSNCAKDM4ENPC1
SCHEMBL12199236 0.85 APP (0.78) APPMAPTSNCASULT1A1KDM4E
SCHEMBL13903820 0.84 MAPT (0.72) APPMAPTSNCAKDM4ENPC1
SCHEMBL13903781 0.84 MAPT (0.72) APPMAPTSNCAKDM4ENPC1
SCHEMBL7531819 0.84 MAPT (0.72) APPMAPTSNCAKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580229-B2 Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2013-11-12 US disclosed
US-8404213-B2 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2013-03-26 US disclosed
US-20130045164-A1 AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2013-02-21 US disclosed
US-8343457-B2 Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2013-01-01 US disclosed
US-20120177572-A1 AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES UNIVERSITY OF PITTSBURGH- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2012-07-12 US disclosed
US-20120095235-A1 THIOFLAVIN DERIVATES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH -- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2012-04-19 US disclosed
US-8147798-B2 baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment; imaging the patient University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2012-04-03 US disclosed
US-20110257407-A1 THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH 2011-10-20 US disclosed
US-7854920-B2 Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole UNIVERSITY OF PITTSBURGH (US) 2010-12-21 US disclosed
US-20080219931-A1 Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies UNIVERSITY OF PITTSBURGH 2008-09-11 US disclosed
US-20080154042-A1 THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION UNIVERSITY OF PITTSBURGH 2008-06-26 US disclosed
US-7351401-B2 Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition UNIVERSITY OF PITTSBURGH (US) 2008-04-01 US disclosed
US-20080021077-A1 Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole UNIVERSITY OF PITTSBURGH 2008-01-24 US disclosed
US-7270800-B2 Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy UNIVERSITY OF PITTSBURGH (US) 2007-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095235-A1 THIOFLAVIN DERIVATES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION APP, MAPT, PSEN2 APP 1/4885MAPT 2/4885SNCA 65/4885
US-20080154042-A1 THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION APP, PSEN2, MAPT APP 1/4885MAPT 3/4885SNCA 92/4885
US-20120177572-A1 AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES TTR, APP, SAAL1 APP 2/4885MAPT 14/4885SNCA 68/4885
US-20130045164-A1 AMYLOID IMAGING AS A SURROGATE MARKER FOR EFFICACY OF ANTI-AMYLOID THERAPIES TTR, APP, SAAL1 APP 2/4885MAPT 14/4885SNCA 68/4885
US-20110257407-A1 THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION APP, PSEN2, MAPT APP 1/4885MAPT 3/4885SNCA 70/4885
US-20080021077-A1 Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole APOL1, APOB, APP APP 3/4885MAPT 6/4885SNCA 52/4885
US-20080219931-A1 Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies TTR, APP, SAAL1 APP 2/4885MAPT 14/4885SNCA 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.